Novo Nordisk (English Wikipedia)

"The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 16 September 2008. Retrieved 25 August 2008.

biospace.com

"Novo Nordisk Acquires Ziylo in Possible $800 Million-Plus Deal". BioSpace. 17 August 2018.
"Novo Nordisk Acquires Emisphere Tech in $1.8 Billion Deal | BioSpace". 6 November 2020.
"Novo Nordisk Completes Acquisition of Emisphere Technologies for $1.35 Billion | BioSpace". 8 December 2020.
"Novo Nordisk to Acquire Dicerna | BioSpace". 18 November 2021.
"Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy". 30 August 2023.
"Novartis, Ono Latest to Announce Billion-Dollar M&A Deals". 5 March 2024.
"Novo Acquires Majority Stake in Austrian Life Sciences Tools Company". 15 May 2024.

bizjournals.com

Lamm, Greg (4 September 2014). "Novo Nordisk cuts jobs at Seattle research facility". bizjournals.com. Retrieved 27 October 2014.

bloomberg.com

Wienberg, Christian (9 August 2023). "Novo's Value Surpasses Denmark GDP After Obesity Drug Boost". Bloomberg News.
Wass, Sanne; Kresge, Naomi (30 April 2024). "The Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire Economy". Bloomberg.
McLaughlin, David; Harris, Andrew M.; Feeley (6 September 2017). "Novo Nordisk Settles U.S. Suit Over Victoza for $58.65 Million". Bloomberg News. Retrieved 6 September 2017.

businesswire.com

"Novo A/S acquires Xellia Pharmaceuticals for US$ 700 million". www.businesswire.com. 21 May 2013.

cnbc.com

"Novo Nordisk sees slower 2020 growth with US insulin prices pressured". CNBC. 5 February 2020. Retrieved 20 April 2020.
Constantino, Annika Kim (10 August 2023). "Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion". CNBC. Retrieved 11 August 2023.
Constantino, Annika Kim (5 February 2024). "Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply". CNBC.
Gilchrist, Karen (8 March 2024). "Novo Nordisk market cap surpasses Tesla on new obesity pill trial data". CNBC. Retrieved 8 March 2024.
Constantino, Annika Kim (24 September 2024). "'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricing". CNBC. Retrieved 25 September 2024.

cnn.com

money.cnn.com

"100 Best Companies to Work For 2010: Full list". Fortune. 2010.

dawnstudy.com

"Study Results". DAWN Study. Novo Nordisk. Retrieved 11 July 2016.

diabetes.org.uk

"Medical alert: Batches of NovoMix 30 FlexPen and Penfill to be recalled". Diabetes UK. Retrieved 25 April 2014.

doi.org

Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
Funnell, M. M. (2006). "The Diabetes Attitudes, Wishes, and Needs (DAWN) Study". Clinical Diabetes. 24 (4): 154–155. doi:10.2337/diaclin.24.4.154.
Funch, D.; Gydesen, H.; Tornøe, K.; Major-Pedersen, A.; Chan, K. A. (2014). "A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs". Diabetes, Obesity and Metabolism. 16 (3): 273–275. doi:10.1111/dom.12230. PMC 4237552. PMID 24199745.

dr.dk

"Sådan snød Novo Nordisk Skat for 3,6 milliarder". Retrieved 5 February 2013.

efpia.eu

"The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 16 September 2008. Retrieved 25 August 2008.

euronews.com

"Denmark's Novo Nordisk invests €2.1 billion in France". Euronews Business. 24 November 2023.

europa.eu

imi.europa.eu

Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 15 October 2009. Retrieved 25 August 2008.

europapress.es

"Novo Nordisk y UNICEF amplían su colaboración para ayudar a prevenir el sobrepeso y la obesidad infantil" [Novo Nordisk and UNICEF expand collaboration to help prevent childhood overweight and obesity] (in Spanish). Europa Press. 25 September 2023.

fastercapital.com

"Corporate Governance and the FTSE4Good Index: A Closer Look".

fiercepharma.com

Wasserman, Emily (16 January 2024). "Novo Nordisk Named on the 2014 FORTUNE 100 Best Companies to Work For® List for Sixth Consecutive Year". Fierce Pharma. Retrieved 26 June 2024.
Dunleavy, Kevin (17 June 2024). "Novo Nordisk CEO Jorgensen agrees to testify before Senate over U.S. pricing of semaglutide products". Fierce Pharma. Retrieved 28 June 2024.
Dunleavy, Kevin (24 June 2024). "Novo Nordisk reveals plan to build mammoth $4.1B plant in North Carolina to help produce Ozempic, Wegovy". Fierce Pharma. Retrieved 26 June 2024.
Bulik, Beth Snyder (11 December 2019). "Novo Nordisk joins UNICEF in global and local efforts to end childhood obesity". Fierce Pharma.
Bulik, Beth (28 September 2016). "Novo Nordisk and Indy driver Charlie Kimball drive partnership to 100-race mark and counting". Fierce Pharma. Retrieved 21 June 2018.

finans.dk

Stegger, Clara (2 December 2022). "Første danske virksomhed nogensinde: Novo Nordisk rammer gigantisk beløb". Finans (in Danish). Retrieved 18 January 2023.

forbes.com

Roush, Ty (16 October 2023). "Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion—Expanding Ozempic Maker's Arsenal". Forbes.

ft.com

Barnes, Oliver (2 October 2024). "Can Eli Lilly become the first $1tn drugmaker?". Financial Times.
"Novo Nordisk sheds 400 staff as it refocuses R&D efforts". Financial Times. 18 September 2018. Retrieved 2 November 2018.

genengnews.com

"Novo Nordisk Joins Ablynx in Up-to-$399M+ Nanobody® Alliance". 25 November 2015.

getrealaboutdiabetes.com

"Anthony Anderson's Type 2 Diabetes Story | Get Real About Diabetes™". www.getrealaboutdiabetes.com. Retrieved 8 May 2024.

greatplacetowork.com

"Fortune 100 Best Companies to Work For® 2017". Great Place To Work®. Retrieved 26 June 2024.

i3diabetes.org.uk

"i3-diabetes programme". i3diabetes.org.uk. Archived from the original on 14 December 2014.

ing.dk

Mølsted, Henning (28 March 2020). "Dual shift at Novo now testing Corona samples" (in Danish). Ingeniøren.

innomed-predtox.com

"InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 25 August 2008.

nih.gov

pubmed.ncbi.nlm.nih.gov

Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
Funch, D.; Gydesen, H.; Tornøe, K.; Major-Pedersen, A.; Chan, K. A. (2014). "A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs". Diabetes, Obesity and Metabolism. 16 (3): 273–275. doi:10.1111/dom.12230. PMC 4237552. PMID 24199745.

ncbi.nlm.nih.gov

Funch, D.; Gydesen, H.; Tornøe, K.; Major-Pedersen, A.; Chan, K. A. (2014). "A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs". Diabetes, Obesity and Metabolism. 16 (3): 273–275. doi:10.1111/dom.12230. PMC 4237552. PMID 24199745.

nj.com

De Poto, Tom (18 April 2013). "Novo Nordisk transforms vacant building into U.S. headquarters". The Star-Ledger. Newark, New Jersey.

nne.com

"About us - learn more about NNE".

nnit.com

"NNIT History". www.nnit.com. Archived from the original on 8 July 2019. Retrieved 24 February 2019.

novonordisk-us.com

press.novonordisk-us.com

"Novo Nordisk launches 'Cities Changing Diabetes' to fight urban diabetes". Novo Nordisk. Retrieved 25 April 2014.

novonordisk.com

"Annual Report 2023" (PDF). Novo Nordisk. Archived from the original (PDF) on 31 January 2024. Retrieved 1 February 2024.
"Who we are". www.novonordisk.com. Retrieved 28 September 2021.
"Novo Nordisk share and ownership structure". Retrieved 24 August 2023.
"Annual Report 2021" (PDF). Novo Nordisk. Archived from the original (PDF) on 7 February 2022. Retrieved 13 March 2022.
"Insulin 100 years".
"Our History". www.novonordisk.com. Archived from the original on 8 July 2019. Retrieved 24 February 2019.
"Biopharmaceutical Research Unit," Novo Nordisk Corporation". novonordisk.com. Retrieved 29 November 2011.

novozymes.com

"Our history". www.novozymes.com. Retrieved 1 September 2023.

nytimes.com

Nelson, Eshe (30 August 2023). "Novo Nordisk Tilts G.D.P. In Denmark". The New York Times. p. B1. ISSN 0362-4331. Retrieved 5 October 2023.
Nelson, Eshe (28 August 2023). "How Ozempic and Weight Loss Drugs Are Reshaping Denmark's Economy". The New York Times. ISSN 0362-4331. Retrieved 25 December 2023.
Nelson, Eshe (20 April 2024). "How Ozempic Is Transforming a Small Danish Town". The New York Times.
Nelson, Eshe (20 April 2024). "It Introduced Ozempic to the World. Now It Must Remake Itself". The New York Times. p. B1.

pharmaphorum.com

"A history of... Novo Nordisk". pharmaphorum. 27 February 2013. Retrieved 7 November 2024.

pmcpa.org.uk

"Novo Nordisk Limited, Eli Lilly and Company Limited, Grünenthal Ltd and Napp Pharmaceuticals Limited named in advertisements". Prescription Medicines Code of Practice Authority (PMCPA). Retrieved 7 February 2011.

rcgp.org.uk

"RCGP statement on partnership with Novo Nordisk".

reuters.com

"Reuters". Reuters.
Roy, Mrinalika; Jacobsen, Stine (1 September 2022). "Novo Nordisk to acquire Forma Therapeutics in $1.1. bln deal". Reuters.
Grover, Natalie (16 March 2023). "Novo Nordisk suspended from UK lobby group". Reuters.

uk.reuters.com

"Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid". 8 January 2018. Archived from the original on 27 November 2018 – via uk.reuters.com.

reviewsmemo.com

"How Effective Is The Diabetes Destroyer System?". reviewsmemo.com.

sec.gov

"Form 6-K". U.S. Securities and Exchange Commission. 3 August 2022.

sustainablebrands.com

read, Bart King Published 8 years ago About a 2 minute (27 January 2012). "Novo Nordisk Ranked World's Most Sustainable Corporation". Sustainable Brands. Retrieved 20 April 2020.{{cite web}}: CS1 maint: numeric names: authors list (link)

telegraph.co.uk

Roland, Denise (24 November 2014) Insulin pioneer sees end in sight for diabetes – and itself The Daily Telegraph, Retrieved 25 November 2014

theguardian.com

Davis, Nicola (16 March 2023). "Firm behind Wegovy slimming jab suspended from UK trade association". The Guardian.
Das, Shanti; Ungoed-Thomas, Jon (18 March 2023). "'Skinny jab' drug firm facing fresh inquiries after 'serious breaches' of industry code". The Guardian.

usatoday.com

Sanders, President Joe Biden and Sen Bernie. "President Biden: Novo Nordisk, Eli Lilly must stop ripping off Americans with high drug prices". USA TODAY. Retrieved 11 July 2024.

washingtonpost.com

Gilbert, Daniel (5 February 2024). "Novo Nordisk buys manufacturing power as it seeks to ramp up Wegovy". The Washington Post.

web.archive.org

"Annual Report 2023" (PDF). Novo Nordisk. Archived from the original (PDF) on 31 January 2024. Retrieved 1 February 2024.
"Annual Report 2021" (PDF). Novo Nordisk. Archived from the original (PDF) on 7 February 2022. Retrieved 13 March 2022.
"Our History". www.novonordisk.com. Archived from the original on 8 July 2019. Retrieved 24 February 2019.
"NNIT History". www.nnit.com. Archived from the original on 8 July 2019. Retrieved 24 February 2019.
"Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid". 8 January 2018. Archived from the original on 27 November 2018 – via uk.reuters.com.
"InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 25 August 2008.
Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 15 October 2009. Retrieved 25 August 2008.
"World Diabetes Foundation website". Archived from the original on 19 September 2008. Retrieved 25 August 2008.
"i3-diabetes programme". i3diabetes.org.uk. Archived from the original on 14 December 2014.

worldcat.org

search.worldcat.org

Nelson, Eshe (30 August 2023). "Novo Nordisk Tilts G.D.P. In Denmark". The New York Times. p. B1. ISSN 0362-4331. Retrieved 5 October 2023.
Nelson, Eshe (28 August 2023). "How Ozempic and Weight Loss Drugs Are Reshaping Denmark's Economy". The New York Times. ISSN 0362-4331. Retrieved 25 December 2023.

worlddiabetesday.org

"Novo nordisk in united effort on world diabetes day". worlddiabetesday.org.

worlddiabetesfoundation.org

"World Diabetes Foundation website". Archived from the original on 19 September 2008. Retrieved 25 August 2008.